36C26126F0008↗
Novartis Pharmaceuticals Corporation received this contract from 261-Network Contract Office 21 (36C261), Department of Veterans Affairs: $679.9K obligated so far for drugs and biologicals. Its period of performance ended 2026-09-30; options could extend it to 2030-09-30.
Key facts · data as of Oct 28, 2026
- Recipient
- Novartis Pharmaceuticals Corporation
- Awarding agency
- Department of Veterans Affairs
- Contracting office
- 261-Network Contract Office 21 (36C261) (36C261)
- Obligated to date
- $679.9K
- Potential value
- $3.40M
- Ends
- 2026-09-30
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 28, 2026.
Cite this page: SpendQuery, Award 36C26126F0008, data as of Oct 28, 2026, https://spendquery.com/award?id=CONT_AWD_36C26126F0008_3600_36F79720D0180_3600
Novartis Pharmaceuticals Corporation: all federal awards · Department of Veterans Affairs: spending · 261-Network Contract Office 21 (36C261): what it buys · The follow-on: recompete brief
LUTATHERA CANCER THERAPY
Up for re-bid: ends 2026-09-30. Recompete brief → · 6505--Rubidium (Rb-82) Generators, 612-C79072, Base: 10/01/26 - 09/30/27 Base plus 1 Option Year ↗
What it is
- Product or service
- Drugs and Biologicals (PSC 6505)
- Industry
- Pharmaceutical Preparation Manufacturing (NAICS 325412)
- Contracting office
- 261-Network Contract Office 21 (36C261) (36C261)
- Competition
- Full and open competition · 1 offer received
- Pricing
- Firm fixed price
- How it was bought
- GSA Schedule · under 36F79720D0180
- Where the work is
- Morris, NJ · district NJ-11
Obligations by fiscal year
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
Every action
1 action since 2025-10-01. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2025-10-01 | 0 | $679.9K | LUTATHERA CANCER THERAPY |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-28). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗